ArticleEndocrine2025
"Evaluation of progranulin expression in parathyroid adenomas and its relationship with clinical parameters".
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeIn the pathogenesis of the primary hyperparathyroidism (PHPT), dysregulation has been observed in extracellular signal-regulated 1/2 (ERK 1/2), c-Jun N-terminal kinase (JNK), and phosphatidylinositol 3 kinase (PI3K) pathways. Progranulin (PGRN) is a glycoprotein found in many tissues and has been observed to activate MAPK, JNK, PI3K pathways in multiple studies. We aim to investigate the progranulin expression in parathyroid adenomas and establish its relationship with clinical parameters and comorbidities in patients with PHPT.
methods182 cases were included in our study, consisting of 102 patients with PHPT and 80 controls. All cases with PHPT were operated and parathyroid adenomas were pathologically confirmed. The PGRN staining patterns were examined by applying anti-granulin (anti-GRN) antibody at 1/300 dilution to the parathyroid samples of the cases.
resultsWithin the patient group, negative staining was observed in 59 (57.8%) samples, mild staining in 26 (25.5%) samples, and strong staining in 17 (16.7%) samples. In the control group, all samples showed strong staining. There was a significant decrease in PGRN staining in the patient group compared to the control group (p < 0.001). There was no significant relationship between the degree of PGRN staining and age, biochemical parameters in patients with PHPT. Patients were compared in terms of PHPT-related complications and PGRN expression, no significant difference was observed.
conclusionOur findings show that adenomas expressed lower PGRN compared to normal parathyroid tissue, suggesting that PGRN expression loss may play an important role in pathogenesis of parathyroid adenomas.
Indexed as
Identifiers
40856958What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.